Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Vlp Biotech Inc. currently manages 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This matter is assigned to examiner AMELIA NICOLE DICKENS. The portfolio's prosecution activity is concentrated in 1 distinct art unit, which suggests a highly specific technical focus for the company's current intellectual property efforts. This concentration allows the company to focus its resources on a single technical field.
AMELIA NICOLE DICKENS serves as the busiest examiner for the company with a pending count of 1. Because there is only a single pending matter and 1 distinct examiner, this individual is responsible for the entirety of the company's active prosecution. This relationship between the pending case and the examiner ensures that the company's current strategy is focused on a single point of contact within the patent office, which can simplify communication.
The presence of 1 distinct art unit for the company's work indicates that the company is not currently diversifying its prosecution across different technical groups. For a practitioner, this means that the outcome of this single matter will define the company's current success rate in the Biotechnology & Pharmaceuticals sector. The workload of 1 for the busiest examiner reflects the total volume of pending actions across the 1 distinct art unit.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| DICKENS, AMELIA NICOLE | 1 | 47.2% | +21.6% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18715507 | IMMUNOGENS TARGETING ANTHRAX | DICKENS, AMELIA NICOLE | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18715507 | IMMUNOGENS TARGETING ANTHRAX | DICKENS, AMELIA NICOLE | — |
| Art Unit | Apps |
|---|---|
| 1645 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18715507 | IMMUNOGENS TARGETING ANTHRAX | DICKENS, AMELIA NICOLE | 1645 | §101§102§103§112 | Non-Final OA | — | Pending | May 31, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialVlp Biotech Inc. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Amelia Nicole Dickens has the most, with 1 of Vlp Biotech Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
